Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication. Alecensa ...

Alectinib is recommended, within its marketing authorisation, as an option for the adjuvant treatment of stage 1B (tumours 4 cm or larger) to 3A ALK-positive non-small-cell lung cancer (NSCLC) after ...

The relatively new paradigm of 'rationally targeted' cancer drug therapies ... HER2, MET and ALK interface with common downstream signaling pathways and 'addiction switching' can occur, either ...

License includes Genprex's Reqorsa® Gene Therapy in Combination with ALK-Inhibitors for the Potential Treatment of ALK-Positive Lung ... pathways that cause replication and proliferation of ...

"Positive preclinical data indicate that REQORSA in combination with ALK inhibitors may provide benefit to patients with ALK-positive (ALK+) lung cancer. We are pleased to be able to protect this ...

REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of ... REQORSA's potential as a therapeutic treatment in combination ...